Danzon, Patricia Munch, 1946-...
Danzon, P. M.
Danzon, Patricia M.
Danzon, Patricia M. 1946-....
Danzon, Patricia Munch
Danzon, Patricia M. (Patricia Munch), 1946-
Patricia Danzon American economist
VIAF ID: 110416527 ( Personal )
Permalink: http://viaf.org/viaf/110416527
Preferred Forms
- 200 _ | ‡a Danzon ‡b Patricia M. ‡f 1946-....
- 100 1 _ ‡a Danzon, P. M.
- 100 1 _ ‡a Danzon, Patricia M
-
-
-
-
- 100 1 _ ‡a Danzon, Patricia Munch
- 100 1 _ ‡a Danzon, Patricia Munch ‡d 1946-
-
- 100 1 _ ‡a Danzon, Patricia Munch, ‡d 1946-
- 100 1 _ ‡a Danzon, Patricia Munch, ‡d 1946-
-
-
- 100 1 _ ‡a Danzon, Patricia Munch, ‡d 1946-...
- 100 0 _ ‡a Patricia Danzon ‡c American economist
4xx's: Alternate Name Forms (19)
5xx's: Related Names (10)
- 510 2 _ ‡a Institute for Civil Justice (U.S.)
- 510 2 _ ‡a National Bureau of Economic Research
- 510 2 _ ‡a National Bureau of Economic Research ‡4 affi ‡4 http://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Oxford University Press
- 510 2 _ ‡a Rand Corporation
- 510 2 _ ‡a United States. Health Care Financing Administration
- 510 2 _ ‡a University of Chicago
- 510 2 _ ‡a University of Pennsylvania / Wharton School
- 510 2 _ ‡a Wharton School
- 510 2 _ ‡a Wharton School ‡4 affi ‡4 http://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Causes of the medical malpractice insurance "crisis" : risks and regulations | |
Civilian earnings of military retirees | |
Contingent fees for personal injury litigation | |
Costs and benefits of the tort system if viewed as a compensation system | |
Cross-National Evidence on Generic Pharmaceuticals Pharmacy vs. Physician-Driven Markets | |
Economic analysis of medical malpractice : three reports. | |
Economic factors in the use of lab. tests ... 1980: | |
Effects of regulation on drug launch and pricing in interdependent markets | |
The effects of tort reforms on the frequency and severity of medical malpractice claims : a summary of research results | |
Les effets de la réglementation des prix sur l'industrie pharmaceutique | |
Factors affecting laboratory test use and prices : executive summary | |
Gap and supplementary insurance in New Zealand : theory, evidence and policy options | |
Global budgets versus competitive cost-control strategies | |
The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s | |
Iyakuhin no kokusai kakaku hikaku | |
The life cycle of pharmaceuticals : a cross-national perspective | |
Medical malpractice theory, evidence, and public policy | |
Mergers and acquisitions in the pharmaceutical and biotech industries | |
n79064774 | |
Options for health care in New Zealand : report for the New Zealand Business Roundtable | |
The Oxford handbook of the economics of the biopharmaceutical industry | |
Price regulation for pharmaceuticals, 1996: | |
Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances | |
"Profits" in hospital laboratories : the effects of reimbursement policies on hospital costs and charges | |
Rate regulation of workers' compensation insurance : how price controls increase costs | |
Reference pricing of pharmaceuticals for medicare: evidence from Germany, the Netherlands and New Zealand | |
The resolution of medical malpractice claims, modeling the bargaining process | |
Solvency regulation in the property/Casualty insurance industry | |
Value-Based Differential Pricing : Efficient Prices for Drugs in a Global Context | |
Why are malpractice premiums so high--or so low? | |
医薬品の国際価格比較 : 講演記錄 |